News-Medical.Net on MSN

Biomimetic platform enhances CAR T therapy for relapsed and refractory leukemia

Chimeric antigen receptor T (CAR T) cell therapy represents a milestone in leukemia treatment. CAR T works by genetically engineering a chimeric antigen receptor on the surface of the patient's T ...
EurekAlert!

T cell-based cancer immunotherapy: Opportunities and challenges

CD8 + cytotoxic T lymphocytes (CTLs) serve as central effectors in cancer immunotherapy by directly eliminating tumor cells. However, current clinical therapies face significant limitations. These ...